Compare Quest Diagnostics Inc (DGX) vs Under Armour Inc Class A (UA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Under Armour Inc Class A — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while Under Armour Inc Class A trades at $4.78 (market cap $2.07B). The key difference: Quest Diagnostics Inc is far larger — about 12.3× Under Armour Inc Class A's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Under Armour Inc Class A for 18 Days on average.
| DGX | UA | |
|---|---|---|
Market Cap | $25.48B | $2.07B |
Volume | 941,866 | 2,680,141 |
Sector | Health | Consumer Cyclical |
52-Week High | $247.45 | $7.88 |
52-Week Low | $173.49 | $3.96 |
Typical Hold Time | 56 Days | 18 Days |
Enterprise Value | $31.23B | $3.05B |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.68% today, with a bullish earnings trend after beating EPS estimates for three consecutive quarters. The stock shows a mixed technical picture with a bearish overall signal but trades near key support at $228. Revenue growth accelerated to $11.04B in 2025, and the company maintains solid profitability with a 9.19% net income margin. Recent news highlights growth in consumer testing and a partnership with Apple Health, though Medicare reimbursement cuts pose a headwind.
The outlook is cautiously optimistic, supported by strong fundamentals and a consensus price target of $250 offering 8% upside. Key opportunities include demand for advanced diagnostics and AI adoption, while risks center on regulatory pressure and rising debt levels. Analyst sentiment is mixed with a slight hold bias, reflecting balanced growth prospects against near-term challenges.
Under Armour (UA) trades at $4.74, up 0.85% with a bullish technical signal despite mixed earnings. The company faces revenue declines and negative profitability with a -9.99% net margin, though valuation metrics like P/S of 0.41 appear attractive. Recent Q2 2026 earnings beat expectations, but guidance has been lowered amid softer consumer demand.
Outlook remains challenging with significant cash burn and competitive pressures. While analyst sentiment is mixed with 39.7% buy ratings, the stock offers speculative value for turnaround investors willing to bear execution risks and ongoing revenue headwinds in the athletic apparel sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →
